dr herbst on the importance of multidisciplinary collaboration in nsclc
Published 2 months ago • 24 plays • Length 2:02Download video MP4
Download video MP3
Similar videos
-
1:03
dr. herbst on combination of nivolumab and ipilimumab in patients with nsclc
-
1:35
dr. herbst on promising immunotherapy combinations in nsclc
-
1:56
dr. herbst on advances of immunotherapy in lung cancer
-
1:18
dr. herbst on next-generation agents in nsclc
-
1:03
dr. herbst on combination therapies for lung cancer
-
2:15
dr. herbst on the next generation of lung cancer trials
-
1:49
dr. herbst on the impact of frontline immunotherapy in lung cancer
-
1:59
dr. herbst on key immunotherapy findings in nsclc
-
1:42
dr. herbst on tmb as a biomarker in nsclc
-
1:35
dr. herbst on the benefit of adjuvant osimertinib in egfr-mutant nsclc
-
1:35
dr. herbst on immuno-oncology combinations in lung cancer
-
1:12
dr. roy herbst on the emergence of immunotherapy in cancer
-
0:58
dr. herbst on immunotherapy in lung cancer
-
1:01
dr. herbst on the international lung cancer congress
-
0:46
dr. herbst on nivolumab for nsclc
-
1:22
dr. herbst on immune resistance in lung cancer
-
1:11
dr. herbst on screening studies at the upcoming lung cancer congress
-
1:23
dr. herbst on themes from the 2011 lung cancer congress
-
1:13
dr. herbst on targeting pd-1 and pd-l1 in lung cancer